{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:51:46Z","timestamp":1793681506974,"version":"4.5.1"},"reference-count":59,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling (GEP) assay, which was developed and trained using 265 formalin-fixed, paraffin-embedded tissue samples on a reliable platform to predict, at the time of diagnosis, whether a patient will experience an event within 24 months. The modeling also confirmed and relied upon previously reported synergy between immune response (IR) gene expression signatures IR1 and IR2. Once locked, the 5-factor logistic regression FL24Cx model was independently validated in a retrospectively assessed cohort of 232 patients from 2 immunochemotherapy-treated arms of SWOG Cancer Research Network S0016 phase 3 clinical trial, in which it assigned 169 patients to the low-risk group with 29 events before 24 months (17.2%) and 63 patients to the high-risk group with 24 events before 24 months (38.1%). The relative risk of an event within 24 months after registration among patients who were classified into the high-risk group relative to patients who were classified into the low-risk group was 2.2 (95% confidence interval, 1.41 to 3.51). An up-front GEP biomarker, such as the FL24Cx, rigorously validated in a clinical laboratory and with a clinically relevant turnaround time, could identify and steer enrollment of patients at high risk for early events in clinical trials, thus enabling timely interpretation of such trials and increasing the pace of innovation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016827","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:13:01Z","timestamp":1758222781000},"page":"6443-6454","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-7712","authenticated-orcid":false,"given":"Colleen A.","family":"Ramsower","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0843","authenticated-orcid":false,"given":"George","family":"Wright","sequence":"additional","affiliation":[{"name":"2Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"3SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mwangi","sequence":"additional","affiliation":[{"name":"4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3163","authenticated-orcid":false,"given":"Allison C.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-1651","authenticated-orcid":false,"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"8Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"3SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"9Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"10Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1420-5563","authenticated-orcid":false,"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"11Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"12Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"14Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"12Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"15Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-2750","authenticated-orcid":false,"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[{"name":"13Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Medicine, The University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"9383","key":"2025122309461375600_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"2025122309461375600_bib2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025122309461375600_bib3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2025122309461375600_bib4","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025122309461375600_bib5","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122309461375600_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025122309461375600_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025122309461375600_bib8","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3324\/haematol.2023.284538","article-title":"Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study","volume":"109","author":"Barraclough","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2025122309461375600_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"2025122309461375600_bib10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2022007949","article-title":"Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy","volume":"7","author":"Rodr\u00edguez-Sevilla","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025122309461375600_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"23","key":"2025122309461375600_bib12","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122309461375600_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41408-024-01150-3","article-title":"Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort","volume":"14","author":"Enemark","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025122309461375600_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2025122309461375600_bib15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","article-title":"Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens","volume":"132","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2025122309461375600_bib16","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025122309461375600_bib17","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"36","key":"2025122309461375600_bib18","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.21.02707","article-title":"Gene expression signatures for the accurate diagnosis of peripheral T-cell lymphoma entities in the routine clinical practice","volume":"40","author":"Amador","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025122309461375600_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025122309461375600_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.19153","article-title":"Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine\u2013rituximab","volume":"204","author":"Ramsower","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122309461375600_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12308-019-00344-0","article-title":"Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B-cell lymphoma","volume":"12","author":"Robetorye","year":"2019","journal-title":"J Hematop"},{"issue":"S3","key":"2025122309461375600_bib22","doi-asserted-by":"crossref","first-page":"e8671011","DOI":"10.1097\/01.HS9.0000976236.86710.11","article-title":"PB2380: developing genomic tests that guide large B-cell lymphoma diagnosis and treatment: Lymph2Cx and Lymph3Cx assays","volume":"7","author":"Robetorye","year":"2023","journal-title":"HemaSphere"},{"issue":"9","key":"2025122309461375600_bib23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025122309461375600_bib24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) cohort study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"21","key":"2025122309461375600_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"2025122309461375600_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025122309461375600_bib27","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.celrep.2019.01.085","article-title":"Mass cytometry analysis reveals that specific intratumoral CD4+ T cell subsets correlate with patient survival in follicular lymphoma","volume":"26","author":"Yang","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"2025122309461375600_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"3","key":"2025122309461375600_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025122309461375600_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122309461375600_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"27","key":"2025122309461375600_bib32","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025122309461375600_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2011.301","article-title":"Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells","volume":"26","author":"Am\u00e9-Thomas","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2025122309461375600_bib34","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1\u2013positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025122309461375600_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3324\/haematol.10682","article-title":"MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes","volume":"92","author":"Naresh","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2025122309461375600_bib36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/10428194.2023.2214651","article-title":"Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP","volume":"64","author":"Nichols","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025122309461375600_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1440-1827.2004.01678.x","article-title":"Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression","volume":"54","author":"Saito","year":"2004","journal-title":"Pathol Int"},{"issue":"5","key":"2025122309461375600_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1078\/0344-0338-00421","article-title":"Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein","volume":"199","author":"Shiozawa","year":"2003","journal-title":"Pathol Res Pract"},{"issue":"1","key":"2025122309461375600_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.56.1","article-title":"Follicular lymphoma: the role of the tumor microenvironment in prognosis","volume":"56","author":"Sugimoto","year":"2016","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"2025122309461375600_bib40","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdp460","article-title":"Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study","volume":"21","author":"Sweetenham","year":"2010","journal-title":"Ann Oncol"},{"issue":"10","key":"2025122309461375600_bib41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.humpath.2014.06.019","article-title":"Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis","volume":"45","author":"Xerri","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"2025122309461375600_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/hon.2778","article-title":"Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma","volume":"38","author":"Xue","year":"2020","journal-title":"Hematol Oncol"},{"issue":"7","key":"2025122309461375600_bib43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-021-00521-4","article-title":"Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma","volume":"11","author":"Mondello","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025122309461375600_bib44","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41598-017-07226-4","article-title":"Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma","volume":"7","author":"Batmanov","year":"2017","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"2025122309461375600_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2019-130255","article-title":"Whole exome and transcriptome sequencing in 1042 cases reveals distinct clinically relevant genetic subgroups of follicular lymphoma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025122309461375600_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"suppl 1","key":"2025122309461375600_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025122309461375600_bib48","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2023-190215","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma: FOXO1 mutational status may be a predictive marker of early progression and long-term outcome","volume":"142","author":"Bantilan","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2025122309461375600_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V126.23.333.333","article-title":"A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy","volume":"126","author":"Vindi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2025122309461375600_bib50","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/annonc\/mdv375","article-title":"Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study\u2020","volume":"26","author":"Casulo","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2025122309461375600_bib51","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2022-157194","article-title":"FLIPI24: an improved international prognostic model developed on early events in follicular lymphoma","volume":"140","author":"Maurer","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025122309461375600_bib52","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"2025122309461375600_bib53","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/01.HS9.0000848012.06176.ae","article-title":"Distinguishing between primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma using the Lymph3Cx gene expression profiling assay","volume":"6","author":"Robetorye","year":"2022","journal-title":"HemaSphere"},{"issue":"5","key":"2025122309461375600_bib54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/bloodadvances.2024014053","article-title":"Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium","volume":"9","author":"Day","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025122309461375600_bib55","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2024-201078","article-title":"Outcomes in early relapse of follicular lymphoma versus early histologic transformation following firstline immunochemotherapy in follicular lymphoma","volume":"144","author":"Casulo","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122309461375600_bib56","doi-asserted-by":"crossref","first-page":"29962","DOI":"10.1038\/s41598-024-81693-4","article-title":"Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation","volume":"14","author":"Enemark","year":"2024","journal-title":"Sci Rep"},{"key":"2025122309461375600_bib57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026016","article-title":"An updated understanding of follicular lymphoma transformation","author":"Parry","year":"15  2025","journal-title":"Blood"},{"issue":"2","key":"2025122309461375600_bib58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025122309461375600_bib59","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2018-99-113675","article-title":"Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma","volume":"132","author":"Freeman","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6443\/2475011\/blooda_adv-2025-016827-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6443\/2475011\/blooda_adv-2025-016827-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:46:22Z","timestamp":1766501182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6443\/547305\/Development-and-validation-of-a-gene-expression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":59,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016827","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}